The role of therapeutic leukapheresis in hyperleukocytotic AML. - Wikidata - wikimedia - TriplyDB

The role of therapeutic leukapheresis in hyperleukocytotic AML.

The role of therapeutic leukapheresis in hyperleukocytotic AML.

http://www.wikidata.org/entity/Q35148107

about

Guidelines on the Use of Therapeutic Apheresis in Clinical Practice-Evidence-Based Approach from the Writing Committee of the American Society for Apheresis: The Seventh Special Issue.Acute promyelocytic leukemia with the translocation t(15;17)(q22;q21) associated with t(1;2)(q42~43;q11.2~12): a case report Initial respiratory status in hyperleukocytic acute myeloid leukemia: prognostic significance and effect of leukapheresis.Hyperleukocytosis and leukostasis: management of a medical emergency.Neurological Complications of the Leukemias Across the Ages.Hyperleucocytosis in paediatric acute myeloid leukaemia - the challenge of white blood cell counts above 200 × 109 /l. The NOPHO experience 1984-2014.The effect of therapeutic leukapheresis on early complications and outcomes in patients with acute leukemia and hyperleukocytosis: a propensity score-matched study.Hyperleukocytosis in infant acute leukemia: a role for manual exchange transfusion for leukoreduction.Therapeutic leukocytapheresis for improvement in respiratory function in a woman with hyperleukocytosis and mantle cell lymphoma with a circulating small lymphocyte phenotype.Physiological measurements corroborate symptomatic improvement after therapeutic leukapheresis in a pregnant woman with chronic myelogenous leukemia.Hyperleukocytosis in acute myeloid leukemia patients is associated with high 30-day mortality which is not improved with leukapheresis.

P2860

Q30276550-FE8C2678-BD83-46A1-ADEB-0EDDC81343E4 Q33434158-0D94E699-DCAF-479E-B37B-D08593E5F629 Q38587662-178FD84D-75EA-4D0D-925F-755D672BE851 Q39038221-F5211C97-7163-4037-A6FC-57E988D2B9B3 Q39147519-CE1DE759-A8C4-4139-9386-F047D28EB9F1 Q48100627-25810068-4CB2-4926-85CF-73E7C5248287 Q48272835-6E2934A0-482D-4CD3-8B62-1667C2D2D5C8 Q49330726-E02AC654-7A88-4915-911B-7679E6CC9D8A Q51598684-F01A811A-6274-44B2-878B-7C327CD31284 Q52938008-902426C4-365D-4D22-B66B-FE53C169DB9F Q53391383-169A0A22-A5F8-4877-B9F8-1B4AAB451EC6

P2860

The role of therapeutic leukapheresis in hyperleukocytotic AML.

http://www.wikidata.org/entity/Q35148107

description

2014 nî lūn-bûn

@nan

2014 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

The role of therapeutic leukapheresis in hyperleukocytotic AML.

@ast

The role of therapeutic leukapheresis in hyperleukocytotic AML.

@en

type

label

The role of therapeutic leukapheresis in hyperleukocytotic AML.

@ast

The role of therapeutic leukapheresis in hyperleukocytotic AML.

@en

prefLabel

The role of therapeutic leukapheresis in hyperleukocytotic AML.

@ast

The role of therapeutic leukapheresis in hyperleukocytotic AML.

@en

P1433

Q35148107-92686FF8-109A-44F0-8EB3-991E52CC52AD

P1476

Q35148107-0C23C221-705A-4CB9-AF26-2D8945836DBA

P2093

Q35148107-59B0B222-D6B6-4D6C-A100-3888B72AAA6E

Q35148107-655F2417-383C-489A-A37E-9C83E4880559

Q35148107-799996EF-D3F0-49C9-B56C-49DF4A263398

Q35148107-853C8668-B945-4FE6-BED8-6BDB13AAB4E3

Q35148107-987BBC61-D863-4BB1-A761-A00D050E9775

P2860

Q35148107-0A9538E5-ECC8-4E8C-9413-DD6CECCCCD4E

Q35148107-207EE15A-2940-4C15-989F-5A35FA988CDB

Q35148107-2A59DDE3-0B5E-47EB-AEB2-4A2A1363A2E8

Q35148107-2AFB344B-6D54-434A-AA93-478E2CABF0D1

Q35148107-31ADAFA7-9A11-40EA-9698-8DE3DE07EF9E

Q35148107-3A7C1E0F-B2D7-4ED7-B3BC-E8FDA60FCB5A

Q35148107-3A90CDBE-D6EE-406A-95C0-595143334395

Q35148107-3E7EF9D7-4FB8-4010-8252-93078FA45225

Q35148107-3F08F78E-B098-478C-ADF9-D2597EF17C58

Q35148107-438D39CF-879B-4E48-9BA1-DDB330267239

P304

Q35148107-B1B66DF2-6CA5-420E-BFDF-B89B267A4987

P31

Q35148107-33C8EDAA-435C-4472-B619-E8A320FABB72

P356

Q35148107-6D8BA3FA-2496-4CE0-BE63-D5871E101D35

P407

Q35148107-2622850D-01DA-44DB-9CA8-7172130FF60D

P433

Q35148107-C9D71951-45F6-41B1-9654-0707E5476D2F

P478

Q35148107-DD4A2F51-C538-4727-94EE-09C99D84017E

P577

Q35148107-FC564F40-71EC-4E94-B0A5-3971BECB5400

P5875

Q35148107-4649D4A1-1E53-4D50-8DDE-0DB9C9DF89D5

P698

Q35148107-B753B366-E686-4B2F-B9B1-5551E900C324

P932

Q35148107-9CC4FA90-8490-4624-B91E-8D283C2E83C9

P356

JOURNAL.PONE.0095062

P1433

P1476

The role of therapeutic leukapheresis in hyperleukocytotic AML.

@en

P2093

Alessandro Pastore

http://www.w3.org/2001/XMLSchema#string

Friederike Pastore

http://www.w3.org/2001/XMLSchema#string

Georg Wittmann

http://www.w3.org/2001/XMLSchema#string

Karsten Spiekermann

http://www.w3.org/2001/XMLSchema#string

Wolfgang Hiddemann

http://www.w3.org/2001/XMLSchema#string

P2860

Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype.

Age-related risk profile and chemotherapy dose response in acute myeloid leukemia: a study by the German Acute Myeloid Leukemia Cooperative Group.

Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461)

Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet

Diagnostic score for heparin-induced thrombocytopenia after cardiopulmonary bypass.

Hyperleukocytic leukemias and leukostasis: a review of pathophysiology, clinical presentation and management.

Molecular rearrangements of the MLL gene are present in most cases of infant acute myeloid leukemia and are strongly correlated with monocytic or myelomonocytic phenotypes.

Guidelines on the use of therapeutic apheresis in clinical practice--evidence-based approach from the Apheresis Applications Committee of the American Society for Apheresis.

Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis.

Acute myeloid leukemia: epidemiology and etiology.

P304

e95062

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1371/JOURNAL.PONE.0095062

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

9

http://www.w3.org/2001/XMLSchema#string

P577

2014-04-14T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

261736959

http://www.w3.org/2001/XMLSchema#string

P698

24733550

http://www.w3.org/2001/XMLSchema#string

P932

3986260

http://www.w3.org/2001/XMLSchema#string